Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Astellas Pips Janssen To Post With English Funding For New Prostate Cancer Indication

Executive Summary

NICE’s decision today affirming the cost effectiveness of Astellas Pharma’s Xtandi for hormone-sensitive metastatic prostate cancer contrasts with the health technology assessment body’s guidance last month for Janssen’s Erleada.

You may also be interested in...



Alexion’s Ultomiris Wins English Funding, Janssen’s Erleada Rejected

Recommendations this week from health technology assessment body NICE relate to the treatment of two rare blood disorders with Ultomiris, and treating prostate cancer with Erleada.

Ophthalmic Bevacizumab Reaches Critical Review Stage In EU

The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.

New EU Filings

Janssen/Legend Biotech's ciltacabtagene autoleucel and Ipsen's palovarotene are among the latest new medicines that have been submitted for pan-EU approval.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144434

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel